Notice of Further Amendment of PAR-18-919 "Quantitative Imaging Tools and Methods for Cancer Response Assessment (R01 Clinical Trial Optional)"

Notice Number: NOT-CA-19-007

Key Dates
Release Date: November 7, 2018

Related Announcements
PAR-18-919
NOT-CA-18-109

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to further amend PAR-18-919 "Quantitative Imaging Tools and Methods for Cancer Response Assessment (R01 Clinical Trial Optional)" to indicate that it is the reissuance of PAR-18-249 and that it also accepts resubmission applications preceded by original submissions in response to PAR-18-249.

The following sections have been modified: 

Part 1. Overview Information 

Currently reads: 

Announcement Type
New

  

Should correctly read (in bold italics):

 

Announcement Type

Reissue (of PAR-18-249 )

 

Section II. Award Information

 

Currently reads: 

Application Types Allowed

New 

Renewal

Resubmission only of PAR-11-150; PAR-14-116; PAR-17-129; or PAR-18-249.

Revision 

The  OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. 

 

Should correctly read (in italics):

New 

Renewal

Resubmission only of PAR-11-150; PAR-14-116; PAR-17-129; PAR-18-249; or PAR-18-919.

Revision 

The  OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.

 

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Robert J. Nordstrom, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5934 
Email:  nordstrr@mail.nih.gov

 Darrell Tata, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5894
Email:  Darrell.Tata@nih.gov